Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 2Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Burkitt Lymphoma 1

Interventions

Rituximab 30Cyclophosphamide 25Filgrastim 19Methotrexate 15fludarabine phosphate 13Etoposide 13Cytarabine 13Peripheral Blood Stem Cell Transplantation 12Cyclosporine 11Vincristine 10Mycophenolic Acid 10Whole-Body Irradiation 9Antilymphocyte Serum 9Radiotherapy 8Granulocyte Colony-Stimulating Factor 8CT-P10 8fludarabine 7Prednisone 7Doxorubicin 7Dexamethasone 7merphos 6Tacrolimus 6Melphalan 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5deltacortene 5auricularum 5Methylprednisolone 5Leucovorin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Burkitt Lymphoma × tisagenlecleucel × Clear all
NCT04225676 2023-01-30

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Novartis

Phase 2 Terminated
5 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡